Zymeworks (ZYME) Q4 2025 earnings summary

Executive summary

• Zanidatamab achieved strong Phase 3 results in HER2-positive GEA, supporting potential to redefine first-line treatment standards and driving regulatory submissions globally, with anticipated U.S. launch in 2H26 and recent approvals in Canada and the UK for BTC.

• Achieved significant clinical and regulatory milestones, including FDA Breakthrough Therapy designation for zanidatamab in HER2+ GEA and ongoing royalty revenue from key partnerships.

• Strategic $250 million royalty-backed note financing with Royalty Pharma provides non-dilutive capital, leveraging only 30% of the Ziihera royalty stream, preserving long-term upside and supporting share repurchases and acquisitions.

• Ongoing share repurchase program with $62.5 million utilized out of $125 million authorized, and disciplined capital allocation to maximize shareholder value.

• Cash runway forecast extends beyond 2028, supported by milestone payments, royalty-backed financing, and robust R&D pipeline.

Financial highlights

• Total revenue for 2025 was $106 million, up 39% from $76.3 million in 2024, driven by milestone achievements and option exercises under collaborations.

• Operating expenses decreased to $198.5 million in 2025 from $213.4 million in 2024, mainly due to a prior year impairment charge.

• Net loss narrowed to $81.1 million in 2025 from $122.7 million in 2024, reflecting higher revenue and lower expenses.

• Cash, cash equivalents, and marketable securities at year-end 2025 were $270.6 million, down from $324.2 million at year-end 2024.

• $41.7 million spent on stock repurchase programs in 2025.

Outlook and guidance

• Cash runway expected to extend beyond 2028, assuming full execution of the $125 million share repurchase plan and receipt of $440 million in anticipated regulatory milestones.

• Adjusted gross operating expenses for 2026 projected to be approximately 20% lower than 2025, excluding acquisitions or new partnerships.

• Expect to complete sBLA submission for zanidatamab in 1Q26 and anticipate a potential U.S. launch in 2H26.

• Top-line data from 1L BTC confirmatory trial anticipated late 2027/early 2028.

• Aggregate adjusted gross operating expenditures targeted at $300 million over three years ending December 2028.